Skip to content
DataLookout
Menu

NCT06818136

Bladder EpiCheck European Haematuria Study

StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Primary completion pushed from Aug 2026 to Dec 2026
    • Study completion pushed from Dec 2026 to Jun 2027
  2. Minor Enrollment target: 600 to 800
    • Study sites: 2 to 5
    • Primary completion date: Feb 2026 to Aug 2026
    • Study completion date: Apr 2026 to Dec 2026
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of Apr 2025 to Jun 20, 2025
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The sensitivity and specificity of Bladder EpiCheck to detect primary urothelial carcinoma
Timeframe: urothelial carcinoma detected within 6 months of enrolment, by the standard of care haematuria work-up

Secondary (2)

Non-inferiority of Bladder EpiCheck overall sensitivity vs. cytology in detection of primary urothelial carcinoma
Non-inferiority of Bladder EpiCheck specificity vs. cytology in detection of primary urothelial carcinoma

Arms and interventions

aged ≥ 45 years with haematuria scheduled for cystoscopy, for suspicion of urothelial carcinoma

Adult participants aged ≥ 45 years presenting with haematuria in the past 6 months, scheduled to undergo haematuria workup, including cystoscopy, for suspicion of urothelial carcinoma.

Diagnostic tests: Bladder EpiCheck

Sites

7 sites in 1 country